Introduction {#sec1}
============

Successful tuberculosis (TB) control depends on rapid detection and treatment of active cases, yet diagnosis is often difficult and delayed. Although sputum smear-positive pulmonary TB is readily diagnosed within hours, diagnosis of extra-pulmonary and smear-negative pulmonary TB can take much longer and bacteriological confirmation is often not possible.[@bib1; @bib2]

Causes for delay in initiation of TB treatment are multiple, and can be visualised along a timeline ([Fig. 1](#fig1){ref-type="fig"}). Studies examining health care system delays have shown that the longest delay is in deciding to initiate treatment.[@bib3; @bib4] Treatment delay is common and prolonged because physicians have to make a presumptive diagnosis whilst still awaiting definitive culture results, knowing that these will frequently be falsely negative.

The tuberculin skin test (TST), which provides evidence of *M. tuberculosis* infection, is widely used to support clinical and radiological findings in the evaluation of patients with suspected tuberculosis.[@bib5] A positive TST result can help in the decision to start treatment while bacteriological confirmation is awaited or lacking. However, the greatest utility of a test of *M. tuberculosis* infection lies in its potential to exclude a diagnosis of TB when other tests are negative. This requires a test with high diagnostic sensitivity to minimise the possibility of falsely ruling out tuberculosis.

The poor sensitivity of TST in young children and immunosuppressed people makes it impossible to interpret negative TST results in these groups. Moreover, up to 25% of immunocompetent adults with active tuberculosis may have a negative or ambiguous result.[@bib6]

A recently developed rapid blood test for *M. tuberculosis* infection, the enzyme-linked immunospot assay (ELISpot), may offer a more accurate alternative to the TST. The assay detects T cells specific for antigens in *M. tuberculosis*, which are absent from BCG and most environmental bacteria.[@bib7] It is therefore not confounded by prior BCG vaccination and is more specific than TST.[@bib7; @bib8; @bib9] ELISpot was found to have a sensitivity of 96% in HIV-negative adults with culture-confirmed active TB,[@bib7] and 92% in HIV-positive patients with pulmonary TB.[@bib10] These attributes suggest that ELISpot could improve and accelerate the diagnostic evaluation of patients with suspected TB.

The regulatory-approved, commercially available ELISpot assay, T-SPOT.*TB* (Oxford Immunotec Ltd, Abingdon, UK) is based on the assay used here, developed by Lalvani.[@bib7; @bib8; @bib9; @bib10] T-SPOT.*TB* and an alternative interferon-gamma release assay, the whole blood ELISA (QuantiFERON-Gold, Cellestis, Carnegie, Australia), have recently been approved by the National Institute for Clinical Excellence (NICE) for diagnosis of latent TB infection and as adjunctive tests for the evaluation of patients with active TB. However, clinical data on the performance of these tests in TB patients and how they will impact on clinical decision-making is limited. The most relevant target population is that in which the test will actually be used in practice: patients presenting with suspected TB whose diagnoses are unknown at the time of testing.[@bib11; @bib12] We therefore monitored the diagnostic performance of ELISpot in patients with suspected TB in routine clinical practice.

We received requests to perform ELISpot assays from physicians at two institutions who were aware of the published literature on ELISpot. The decision to request an ELISpot blood test was made by the referring physicians and arose from their routine clinical practice. To date, 13 patients with suspected active TB have been tested and we report the comparative performance of ELISpot and TST and discuss how the availability of ELISpot results enabled early initiation of treatment.

Methods {#sec2}
=======

Study population {#sec2.1}
----------------

Six child and seven adult inpatients from the Departments of Pulmonary Medicine and Paediatrics, Modena University Hospital, Italy, and the Department of General Internal Medicine, Battle Hospital, Reading, UK, being investigated for suspected tuberculosis, were referred for ELISpot testing. None had symptoms or signs of HIV infection or were suspected of HIV carriage, and all were from populations at low risk of HIV. Of the 13, seven had a final diagnosis of active tuberculosis ([Tables 1 and 2](#tbl1 tbl2){ref-type="table"}). All patients, or their parents, gave verbal informed consent to have an ELISpot blood test. Ethical approval was granted by Central Oxford Research Ethics Committee, Modena University Hospital Ethics Committee and the Battle Hospital Ethics Committee.

Procedures {#sec2.2}
----------

ELISpot was performed as previously described using 35 overlapping peptides spanning the length of ESAT-6 and CFP10 arranged in six pools and 250,000 peripheral blood mononuclear cells were added to each ELISpot well.[@bib9] All assays produced evaluable results. The assays were carried out within 1 week of initial presentation to the hospital. Both ELISpot and TSTs were performed during the diagnostic evaluation period before therapy was commenced. Twelve of the thirteen TSTs were performed using the Mantoux method in accordance with guidelines. Five international units of purified protein derivative (PPD) were injected intradermally and the tests were interpreted within 72 h. A positive result was defined as greater than 5 mm regardless of BCG status. Case 4 had a Heaf test performed via the standard method using a six-needle disposable Heaf gun injecting 100,000 units per ml of PPD, and was read 1 week afterwards.[@bib9] All tests were interpreted by an experienced physician.

Results and discussion {#sec3}
======================

Of the 13 patients, seven had a final diagnosis of active TB. Of these, two were culture-confirmed, one was confirmed by nucleic acid amplification and the remaining four were diagnosed on clinical and radiological grounds. All had an excellent response to anti-TB therapy ([Table 1](#tbl1){ref-type="table"}). Active TB was clinically and microbiologically excluded in the remaining six patients ([Table 2](#tbl2){ref-type="table"}). Of these, two were negative by TST and ELISpot (one with pneumonia, the other with bronchiectasis, cases 8 and 9); three were positive by TST and ELISpot and were treated for latent TB infection and one, a 7-month-old infant with recent TB exposure and respiratory symptoms, had a positive ELISpot but negative TST, and was treated for latent TB infection (case 13). All six have remained well over 18 months follow-up.

All seven active TB cases were ELISpot positive but three were TST negative at presentation. Of these three, case 1 presented with pyrexia and night sweats and had inconclusive radiological findings. Although TB was in the differential diagnosis, there was no definitive evidence, and acid fast stains and the skin test were negative. The positive ELISpot result, performed 3 days after the negative skin test, provided the only specific evidence for TB infection, making a diagnosis of TB much more likely and prompting early initiation of therapy which resulted in an excellent clinical response. Initiation of anti-TB treatment would otherwise likely have been delayed several weeks. Case 2 presented with constrictive pericarditis and pulmonary nodules. Although the clinical picture was compatible with TB, acid fast stains, culture of bronchoalveolar lavage fluid and pericardial biopsy tissue were negative, as was the skin test. A positive ELISpot result provided definitive evidence of TB infection, prompting the presumptive diagnosis of tuberculous pericarditis and initiation of anti-tuberculous chemotherapy just 4 days after admission. Case 7 was a heavy smoker presenting with cough and haemoptysis and two nodules in the right upper lung, a picture highly suggestive of lung cancer. However the positive ELISpot result---despite the negative TST result---suggested a diagnosis of pulmonary TB, then confirmed by surgical biopsy which revealed caseating granulomas and was positive on nucleic acid amplification.

Anergy is defined as the absence of the cutaneous delayed type hypersensitivity (DTH) response to PPD during active tuberculosis. These cases suggest that the ELISpot is less susceptible to this anergy, giving fewer false-negative results. None of the three cases with active TB and a negative skin test had intrinsic or iatrogenic immunosuppression to account for the negative skin test results. Therefore, these false-negative results were likely caused by the active tuberculosis per se. The ability of ELISpot to detect TB infection in the setting of anergic skin test results is likely due to the fact that a greater number of *M. tuberculosis* antigen specific Th1-type T cells are required to produce a cutaneous DTH response than an ELISpot response.[@bib13]

Our report has several limitations. Only two of seven TB patients had a gold-standard culture-confirmed microbiological diagnosis. However, the clinical and radiological picture in the remaining cases was either compatible with or strongly suggestive of active TB and was further corroborated by the excellent response to anti-TB therapy in each case. Performance of ELISpot in patients with a clinical diagnosis of TB is highly relevant for clinical practice, where culture-confirmation is not possible in a significant proportion of patients.

Of the 13 patients with suspected TB, 11 had positive ELISpot results of whom seven were treated for active disease ([Table 1](#tbl1){ref-type="table"}). In the remaining four ELISpot-positive patients, active TB was clinically and microbiologically excluded and they were treated for latent TB infection; three of these patients also had positive TST results ([Table 2](#tbl2){ref-type="table"}). Thus, as expected for a test of infection, ELISpot did not help in differentiating active TB disease from latent TB infection, which remains a distinction based on clinical judgement.

The numbers are small but likely to be representative of patients presenting to hospital with suspected active TB in general, as they were referred from routine clinical practice. However, it is difficult to rule out possible selection bias employed by the requesting physicians. As collaborating physicians who were aware of the ELISpot test, they are also potentially not representative of the majority of doctors.

In summary, we have presented three cases of active tuberculosis with a negative tuberculin skin test and a positive ELISpot. In each of these cases the ELISpot assay enabled a diagnosis to be reached more rapidly than would have otherwise been possible, allowing rapid treatment initiation. The ELISpot has shown greater sensitivity as a diagnostic test compared to the TST in latent TB[@bib9] and active TB.[@bib7] Our preliminary findings suggest that this increased sensitivity can result in improved diagnostic evaluation of TB suspects with false-negative TST results in routine clinical practice.

This work was supported by the Wellcome Trust.

![Demonstration of how periods of delay arise before treatment of active TB is initiated.](gr1){#fig1}

###### 

Clinical characteristics and test results of the seven active tuberculosis cases

                                                     Case 1                                                                                                                                               Case 2                                                                                               Case 3                                                                                          Case 4                                                                                                                 Case 5                                                                                   Case 6                                                               Case 7
  -------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- -------------------------------------------------------------------- ---------------------------------------------------------------
  Age (years)                                        65                                                                                                                                                   54                                                                                                   71                                                                                              27                                                                                                                     2                                                                                        1.5                                                                  68
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Sex                                                M                                                                                                                                                    M                                                                                                    F                                                                                               F                                                                                                                      M                                                                                        M                                                                    M
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Clinical features                                  Swinging pyrexia and night sweats                                                                                                                    Dyspnoea, constrictive pericarditis                                                                  Arthralgia, pyrexia and back pain                                                               Weight loss, pyrexia and cough                                                                                         Weight loss, pyrexia and cough                                                           Productive cough and weight loss                                     Cough and haemoptysis
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Radiology                                          Bilateral pleural effusions and ascites                                                                                                              Pericardial thickening and pulmonary miliary nodules on HRCT[a](#tblfn1){ref-type="table-fn"}        Para-aortic lymphadenopathy and enlarged right hilum on HRCT[a](#tblfn1){ref-type="table-fn"}   Bilateral nodular opacities in upper lobes. Nodular lesions and tree in bud on HRCT[a](#tblfn1){ref-type="table-fn"}   Hilar lymphadenopathy                                                                    Right hilar node enlargement and parenchymal upper lobe infiltrate   Two small nodules in right upper lung
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Microbiology and histology                         Sputum, pleural and ascitic fluid: ZN[b](#tblfn2){ref-type="table-fn"} stain and culture negative. Pleural and ascitic fluid: lymphocytic exudates   Pericardial biopsy: granuloma. BAL[c](#tblfn3){ref-type="table-fn"}: ZN stain and culture negative   No samples obtained; biopsy refused                                                             Sputum and BAL[c](#tblfn3){ref-type="table-fn"}: ZN[b](#tblfn2){ref-type="table-fn"} stain and culture negative        Gastric washings: ZN[b](#tblfn2){ref-type="table-fn"} stain negative, culture positive   Gastric washings: culture positive                                   Lung biopsy: granulomas with central necrosis
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Basis for final diagnosis of TB                    Clinical picture, response to therapy                                                                                                                Clinical and radiological picture, response to therapy                                               Clinical and radiological picture, response to therapy                                          Clinical and radiological picture, response to therapy                                                                 Culture confirmed                                                                        Culture confirmed                                                    Positive nuclei acid amplification on tissue sample from lung
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Site of disease                                    Pleural effusion + ascites                                                                                                                           Pulmonary (miliary) + pericardial                                                                    Para-aortic lymph nodes                                                                         Pulmonary                                                                                                              Pulmonary                                                                                Pulmonary                                                            Pulmonary
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  BCG vaccination status                             BCG vaccinated                                                                                                                                       Unvaccinated                                                                                         BCG vaccinated                                                                                  Unvaccinated                                                                                                           Unvaccinated                                                                             Unvaccinated                                                         Unvaccinated
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Mantoux result                                     0 mm                                                                                                                                                 0 mm                                                                                                 Heaf grade 4                                                                                    10 mm                                                                                                                  25 mm                                                                                    9 mm                                                                 0 mm
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ELISpot Results[d](#tblfn4){ref-type="table-fn"}   Positive                                                                                                                                             Positive                                                                                             Positive                                                                                        Positive                                                                                                               Positive                                                                                 Positive                                                             Positive

High resolution computerised tomography.

Ziel Nielson.

Bronchioalveolar lavage.

Duplicate pairs of wells were scored positive if they contained a mean of at least five spot-forming cells more than the mean of the negative control wells, and, in addition, this number was at least twice the mean of the negative control wells.

###### 

Clinical characteristics and test results of the six cases without active tuberculosis

                                                     Case 8                                                                                                                                Case 9                                                                                                 Case 10                                                                                                                                      Case 11                                                                                  Case 12                                                                       Case 13
  -------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  Age                                                1 year                                                                                                                                3 years                                                                                                52 years                                                                                                                                     5 years                                                                                  62 years                                                                      7 months
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Sex                                                F                                                                                                                                     M                                                                                                      F                                                                                                                                            F                                                                                        M                                                                             M
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Clinical features                                  Respiratory symptoms; TB contact                                                                                                      Previously treated TB. Immigrant from TB endemic area                                                  Cough and low grade fever                                                                                                                    Cough and low grade fever. Previously treated for LTBI. Immigrant from TB endemic area   TB contact.                                                                   Respiratory symptoms. TB contact
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Radiology                                          Pulmonary parenchymal consolidation                                                                                                   Fibrotic changes on chest x-ray                                                                        Small calcified nodule in upper left lobe                                                                                                    Normal chest x-ray                                                                       Fibrotic changes on chest x-ray                                               Pulmonary parenchymal consolidation
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Microbiology and histology                         Gastric and respiratory aspirate negative for *M. tuberculosis* (microscopy, PCR and culture); culture positive for *H. influenzae*   Gastric aspirate negative for *M. tuberculosis* (microscopy, PCR and culture)                          Sputum and BAL negative for *M. tuberculosis*                                                                                                Gastric aspirate negative for *M. tuberculosis* (microscopy, PCR and culture)            Sputum and BAL negative for *M. tuberculosis* (microscopy, PCR and culture)   Gastric aspirate negative for *M. tuberculosis* (microscopy, PCR and culture)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Basis for final exclusion of TB                    Clinical response to antibiotic therapy for community-acquired pneumonia. Final diagnosis: bacterial pneumonia                        Negative microbiology, no symptoms. Final diagnosis: previously treated TB leading to bronchiectasis   Clinical response to first-line antibiotics for community-acquired chest infection. Final diagnosis: LTBI[b](#tblfn6){ref-type="table-fn"}   Symptoms self-limiting. Final diagnosis: LTBI[b](#tblfn6){ref-type="table-fn"}           Final diagnosis: LTBI[b](#tblfn6){ref-type="table-fn"}                        Clinical response to first-line antibiotics for community-acquired chest infection. Final diagnosis: LTBI[b](#tblfn6){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Mantoux result                                     Negative (0 mm)                                                                                                                       Negative (3 mm)                                                                                        Positive (20 mm)                                                                                                                             Positive (45 mm)                                                                         Positive (14 mm)                                                              Negative (0 mm)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ELISpot results[a](#tblfn5){ref-type="table-fn"}   Negative                                                                                                                              Negative                                                                                               Positive                                                                                                                                     Positive                                                                                 Positive                                                                      Positive

Duplicate pairs of wells were scored positive if they contained a mean of at least five spot-forming cells more than the mean of the negative control wells, and, in addition, this number was at least twice the mean of the negative control wells.

LTBI, latent TB infection. All patients diagnosed with LTBI remained well during 18 months follow-up without treatment for active TB.
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